Subcutaneous Injection vs IV Drip Versions of Immunotherapy

The antibody is identical. Intravenous immunotherapy is dripped into a vein through a cannula or a port over roughly 30 to 60 minutes. Subcutaneous immunotherapy is the same antibody, more concentrated, combined with a hyaluronidase enzyme and injected under the skin of the abdomen or thigh in a few minutes.

The enzyme is the reason the injection is possible at all. Tissue under the skin is held together by hyaluronan, which normally stops a large volume of fluid spreading. Hyaluronidase breaks that mesh down temporarily, so several millilitres of a concentrated antibody can be absorbed instead of forming a painful lump. The effect is local and reverses within about a day.

That is the whole innovation. It is a delivery change, not a new drug and not a new mechanism. Understanding that is what keeps expectations sensible: nothing about the cancer, the eligibility criteria or the monitoring schedule changes because the needle went somewhere else.

The approval trials were designed to show that the body is exposed to a comparable amount of drug by either route. They were not designed to show that one route treats cancer better. Both met their pharmacokinetic targets. Response rates were reported as descriptive secondary findings, and they were broadly similar.

That distinction matters, because it is where most reporting on these approvals goes wrong. A pharmacokinetic non-inferiority trial asks a narrow question: does the injection deliver drug exposure within an agreed margin of the drip? If it does, the regulator accepts that the efficacy already established for the intravenous product carries across. Nobody ran a trial powered to prove the injection shrinks tumours better, and nobody has claimed one.

Read those figures for what they are. They are descriptive outcomes in a specific trial population, reported alongside the pharmacokinetic result that actually drove the approval. They are not a prediction for any individual, and they are not a reason to prefer one route over the other. The US FDA noted no notable difference in progression-free or overall survival between the two arms of the pembrolizumab study.

The honest summary is the dull one. If your oncologist offers you a subcutaneous version of a drug you were going to receive anyway, the expected benefit against your cancer is the same. What changes is the shape of the appointment.

Sources: US FDA approval notices for nivolumab and hyaluronidase-nvhy (27 December 2024) and pembrolizumab and berahyaluronidase alfa-pmph (19 September 2025). See the nivolumab notice and the pembrolizumab notice.

Three checkpoint inhibitors have a subcutaneous formulation approved in the United States: atezolizumab in September 2024, nivolumab in December 2024 and pembrolizumab in September 2025. As of August 2026 we could not confirm a CDSCO approval or an Indian launch for any of the three. Treat the Indian status as unconfirmed.

“Unconfirmed” is deliberate wording. It is not the same as “not approved”, and it is certainly not the same as “coming soon”. Regulatory status changes, and it changes without a press release most of the time. The reliable check is your treating hospital’s pharmacy and the CDSCO listings, not a search result.

This route is not new to oncology

Subcutaneous antibodies have been part of cancer care for years. Rituximab and trastuzumab have had under-the-skin formulations internationally for well over a decade, both using the same hyaluronidase approach and both given as a fixed dose rather than one worked out from body size. What is new is that the checkpoint inhibitors have now followed.

Two practical points follow from that history. The first is that the concept is well understood and not experimental. The second is that a subcutaneous version of one drug tells you nothing about the availability of a subcutaneous version of another; each formulation is registered separately, country by country.

If anyone offers you a subcutaneous checkpoint inhibitor in India, ask in writing which regulatory approval it is supplied under, who imported it, and how the cold chain was maintained. That is a reasonable question, and a legitimate supplier will answer it without difficulty.

It takes less time, but less than the headline suggests. It does not reliably cost less. Where these formulations have launched, they have generally been priced in line with the intravenous versions rather than below them, so the saving is in chair time and vein access, not in the price of the drug.

For a working-age patient trying to hold on to a job through treatment, the time question is the one that actually matters, so it is worth being precise about it. The injection itself takes a couple of minutes instead of half an hour. The appointment does not shrink by the same proportion, because most of a treatment visit was never the infusion.

In the time-and-motion study reported alongside the subcutaneous pembrolizumab approval, patients spent 47.4% less time in the treatment room, a weighted mean of about 67 minutes against about 127 minutes. That is a real and meaningful reduction. It is not a five-minute appointment.

A treatment visit is made up of roughly these parts, and the route changes only one of them.

1. Registration and pre-cycle blood tests — unchanged. Thyroid, liver, kidney and blood-count values are checked before every cycle, whichever route is used.
2. Waiting for the results and the doctor’s review — unchanged, and usually the longest single block of the day.
3. Pharmacy preparation — shorter with a ready-to-use subcutaneous vial than with a bag that has to be compounded, but not eliminated.
4. The dose itself — this is the part that collapses from roughly half an hour to a couple of minutes.
5. Observation afterwards — unchanged. You are still watched for a reaction before you go home.

On cost, be sceptical of any claim in either direction. A subcutaneous product is a separately manufactured, separately priced presentation, and the price it launches at in one country says nothing about what it would cost in another. No Indian price appears on this page for two reasons: there is no confirmed Indian launch to price, and no rate is published here against a named molecule in any case.

If you are ever quoted a figure for either route, ask for it dated, itemised and in writing, with the drug separated from the day-care, nursing, laboratory and imaging lines. Ask your insurer separately whether the formulation you are being offered is covered — a newer presentation of a familiar drug is exactly the kind of thing a policy can decline.

The immune-related risks are the same, because the drug and its mechanism are unchanged. The thyroid, gut, lungs, liver, skin, heart and hormone glands can all be affected either way, and the monitoring schedule does not relax. What is genuinely new is the injection-site reaction.

Local reactions — redness, swelling, pain, itching or a firm area where the needle went in — are specific to the subcutaneous route and are generally mild. The added hyaluronidase enzyme is also an ingredient the body can react to, which is why a previous reaction to a hyaluronidase-containing product is taken seriously.

Everything else is unchanged, including the part that matters most. Immune-related adverse events are defined as much by when they appear as by what they are. Skin and thyroid changes tend to show earliest. Colitis, hepatitis and pneumonitis often appear later in a course, and some events surface weeks or months after the final dose, whichever route delivered it.

Symptoms that need urgent assessment, not home management: new or worsening breathlessness, or a persistent dry cough; loose motions that increase in number or contain blood; chest pain or palpitations; severe unexplained fatigue with dizziness, vomiting or collapse; yellowing of the eyes or skin. For any of these, contact your treating oncology team immediately or go to the nearest emergency department. Do not self-medicate and do not wait for the next scheduled visit. Tell any doctor who sees you, in any department, that you are on immunotherapy.

A shorter appointment can create a false sense that the treatment has become minor. It has not. The escalation path for a new symptom is identical to the one you would follow on the drip.

The route is one of the few decisions in an immunotherapy plan where a patient’s own circumstances legitimately carry weight, so it is reasonable to raise it. Five questions cover it.

1. Does the drug I am prescribed have a subcutaneous form, and is that form actually available to this hospital? These are two separate questions, and the second is the one that gets skipped.
2. Under what approval would it be supplied here? If the answer is vague, that is the answer.
3. How much shorter would my visit realistically be? Ask for the whole-visit estimate, not the injection time.
4. Does anything change about my blood tests, scans or follow-up? It should not, and a confident “no” is the right answer.
5. What would it cost, itemised, and would my policy cover it? Get both answers in writing before, not after.

If the intravenous route is working and tolerable, there is no clinical argument for changing it. Convenience is a real consideration, but it sits below the treatment plan, not above it.

The subcutaneous products are all given as a fixed dose rather than one worked out from body weight, which is the same convention most intravenous checkpoint inhibitors now follow. Why that is, and what it means for a lighter or heavier patient, is set out in How Immunotherapy Doses Are Calculated: mg/kg vs Flat Dose.

For the checkpoint inhibitors that have no under-the-skin version at all, the intravenous mechanics are worth reading in context: Avelumab (Bavencio): Uses and Availability in India covers a fortnightly infusion with its own premedication routine. Rituximab: Uses, Cost and Side Effects covers the antibody that pioneered the subcutaneous route in cancer care long before the checkpoint inhibitors adopted it.

For the wider view across the checkpoint inhibitors, biosimilars and the other medicine classes, start from Immunotherapy Medicines Explained, or from the main immunotherapy section.